Breast cancer cells, after MYC/KRAS- or MYC/ERBB2- ablation (207), are similar to glioma cells in their acquired resistance to phosphoinositol-3-kinase (PIK3) inhibitors (208). This evidence concerns the gene ERBB2 and breast carcinoma.